United Therapeutics Corporation
UTHR
$307.24
$1.850.61%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 38.78% | 15.51% | 7.29% | 27.27% | 64.35% |
| Total Depreciation and Amortization | 43.80% | 43.61% | 44.96% | 12.78% | 3.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.34% | 86.53% | 227.41% | 328.79% | -83.59% |
| Change in Net Operating Assets | 95.42% | -71.74% | 39.32% | -68.71% | -4.44% |
| Cash from Operations | 126.41% | 8.95% | 118.44% | 0.45% | 17.55% |
| Capital Expenditure | -10.17% | -16.44% | -0.89% | 7.51% | -99.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -117.38% | 84.50% | 80.88% | 530.20% | 240.19% |
| Cash from Investing | -392.64% | 63.34% | 64.79% | 432.56% | 122.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 250.68% | 365.38% | 110.93% | -28.86% | -86.85% |
| Repurchase of Common Stock | -200.00% | -100.00% | -- | -7,391.85% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 0.00% | -- |
| Cash from Financing | 19.50% | -943.42% | -294.33% | -2,297.53% | -267.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.30% | 390.59% | 208.32% | -78.35% | 1,885.71% |
